M. Atsukawa

Supplementary Material for: Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab

figshare admin karger, Tanaka E., T. Tada (7719395), Hiraoka A. et autres

Abstract Aim The lymphocyte-to-monocyte ratio (LMR) has emerged as a potential immune-related biomarker; however, its prognostic significance in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atezo/Bev) remains unclear. To investigate the prognostic significance of the LMR in patients …

ch (code pays fourni par la source)

Supplementary Material for: Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab

figshare admin karger, Tanaka E., T. Tada (7719395), Hiraoka A. et autres

Abstract Aim The lymphocyte-to-monocyte ratio (LMR) has emerged as a potential immune-related biomarker; however, its prognostic significance in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atezo/Bev) remains unclear. To investigate the prognostic significance of the LMR in patients …

ch (code pays fourni par la source)

Incidence and risk factors of esophagogastric varices bleeding in cirrhotic patients with advanced hepatocellular carcinoma treated with lenvatinib

M. Iavarone, E. Alimenti, T. Tada, S. Shimose et autres

Supplementary Material for: Incidence and predictors of esophagogastric varices bleeding in patients with hepatocellular carcinoma in lenvatinib

M. Iavarone, E. Alimenti, Toshifumi Tada, S. Shimose et autres

Introduction: Lenvatinib is indicated for the forefront treatment of advanced hepatocellular carcinoma (aHCC), but its use maybe limited by the risk of esophagogastric varices (EGV) bleeding. This study assessed the prevalence, predictors, and complications of EGV in aHCC patients treated with lenvatinib. …

Supplementary Material for: Incidence and predictors of esophagogastric varices bleeding in patients with hepatocellular carcinoma in lenvatinib

M. Iavarone, E. Alimenti, Toshifumi Tada, S. Shimose et autres

Introduction: Lenvatinib is indicated for the forefront treatment of advanced hepatocellular carcinoma (aHCC), but its use maybe limited by the risk of esophagogastric varices (EGV) bleeding. This study assessed the prevalence, predictors, and complications of EGV in aHCC patients treated with lenvatinib. …

Supplementary Material for: Incidence and predictors of esophagogastric varices bleeding in patients with hepatocellular carcinoma in lenvatinib

M. Iavarone, E. Alimenti, Toshifumi Tada, S. Shimose et autres

Introduction: Lenvatinib is indicated for the forefront treatment of advanced hepatocellular carcinoma (aHCC), but its use maybe limited by the risk of esophagogastric varices (EGV) bleeding. This study assessed the prevalence, predictors, and complications of EGV in aHCC patients treated with lenvatinib. …

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection with and without cirrhosis

Kazuaki Chayama, F. Suzuki, K. Sato, T. Atarashi et autres